VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Growth in Short Interest

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 3,385,220 shares, an increase of 88.9% from the December 15th total of 1,791,894 shares. Based on an average trading volume of 10,198,793 shares, the short-interest ratio is currently 0.3 days. Currently, 8.8% of the shares of the stock are short sold. Currently, 8.8% of the shares of the stock are short sold. Based on an average trading volume of 10,198,793 shares, the short-interest ratio is currently 0.3 days.

VistaGen Therapeutics Stock Performance

VTGN opened at $0.70 on Thursday. The firm has a 50-day moving average of $2.79 and a 200 day moving average of $3.09. VistaGen Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $5.14. The firm has a market cap of $27.71 million, a P/E ratio of -0.37 and a beta of 0.31.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.16 million. Equities research analysts predict that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on VTGN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, October 8th. Jefferies Financial Group reissued a “hold” rating and issued a $0.90 price target (down previously from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. William Blair restated a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Wall Street Zen downgraded shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $0.95.

Hedge Funds Weigh In On VistaGen Therapeutics

A number of large investors have recently modified their holdings of the company. AdvisorShares Investments LLC grew its position in VistaGen Therapeutics by 1.9% during the third quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock worth $735,000 after buying an additional 3,884 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of VistaGen Therapeutics in the 1st quarter valued at about $25,000. Schonfeld Strategic Advisors LLC bought a new position in VistaGen Therapeutics during the 3rd quarter worth approximately $39,000. Boothbay Fund Management LLC increased its stake in VistaGen Therapeutics by 10.8% in the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock worth $699,000 after purchasing an additional 19,166 shares during the period. Finally, Bank of America Corp DE grew its holdings in shares of VistaGen Therapeutics by 1,068.0% in the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares during the last quarter. 78.39% of the stock is currently owned by institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.